<DOC>
	<DOCNO>NCT01425190</DOCNO>
	<brief_summary>This study determine pharmacokinetics ( PK ) weight-based dose boceprevir follow single oral dose administration Chronic Hepatitis C Virus ( HCV ) pediatric participant .</brief_summary>
	<brief_title>Pharmacokinetics Boceprevir Pediatric Subjects With Chronic Hepatitis C Genotype 1 ( P07614 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Documented chronic hepatitis C ( CHC ) genotype 1 infection Treatment naïve fail previous interferon/ribavirin therapy ( ≥12 uninterrupted week ) Weigh 10 kg 90 kg inclusive screening baseline ( Day 1 ) . Body Mass Index ( BMI ) 5th 95th percentile participant 's age gender , inclusive , per table Center Disease Control Prevention , USA Use acceptable method contraception least 3 month prior baseline continue study Coinfection human immunodeficiency virus ( HIV ) hepatitis B virus ( HBsAg positive ) . Treatment ribavirin within 90 day , interferonalfa within 30 day Discontinued interferon treatment due adverse event Currently receive antiviral/immunomodulating therapy hepatitis C Prior treatment HCV protease inhibitor Prior treatment know hepatotoxic agent ( include herbal remedy ) Use investigational drug within 30 day enrollment study Evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy . Substance abuse ( include limit alcohol abuse , illicit drug , inhalational drug , marijuana use , etc ) time prior entry study Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . Pregnant breastfeed female Meeting laboratory exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>